サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1210191

コロナウイルス（COVID-19）最新治療薬の世界市場レポート 2023年

Coronavirus (COVID-19) Current Therapy Global Market Report 2023
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
コロナウイルス（COVID-19）最新治療薬の世界市場レポート 2023年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

2022年のコロナウイルス（COVID-19）最新治療薬市場は、北米が最大地域です。中東は予測期間中に最も急速に成長する地域と予想されます。コロナウイルス（COVID-19）最新治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 コロナウイルス（COVID-19）最新治療薬市場の特徴

第3章 コロナウイルス（COVID-19）最新治療薬市場の動向と戦略

第4章 コロナウイルス（COVID-19）最新治療薬市場- マクロ経済シナリオ

  • COVID-19が市場に与える影響
  • ウクライナ・ロシアの戦争が市場に与える影響
  • 高インフレが市場に与える影響

第5章 コロナウイルス（COVID-19）最新治療薬市場の規模と成長

  • 世界のコロナウイルス（COVID-19）最新治療薬市場の実績、2017～2022年
    • 市場の促進要因
    • 市場の抑制要因
  • 世界のコロナウイルス（COVID-19）最新治療薬市場の予測、2022-2027F、2032F
    • 市場の促進要因
    • 市場の抑制要因

第6章 コロナウイルス（COVID-19）最新治療薬市場セグメンテーション

  • 世界のコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • レムデシビル
  • ヒドロキシクロロキン
  • リトナビル
  • ロピナビル
  • インターフェロンベータ
  • その他の薬剤タイプ
  • 世界コロナウイルス（COVID-19）最新治療薬市場、投与経路別のセグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 経口
  • 静脈内
  • 世界コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 病院
  • 診療所
  • 研究
  • その他のエンドユーザー

第7章 コロナウイルス（COVID-19）最新治療薬市場の地域および国の分析

  • 世界コロナウイルス（COVID-19）最新治療薬市場、地域別、実績と予測、2017-2022、2022-2027F、2032F
  • 世界コロナウイルス（COVID-19）最新治療薬市場、国別、実績と予測、2017-2022、2022-2027F、2032F

第8章 アジア太平洋のコロナウイルス（COVID-19）最新治療薬市場

  • アジア太平洋コロナウイルス（COVID-19）最新治療薬市場概要
  • 地域情報, COVID-19の影響,市場情報,背景情報,政府のイニシアチブ,規制,規制機関,主要団体,課税される税,法人税構造,投資,主要企業
  • アジア太平洋コロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • アジア太平洋コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第9章 中国のコロナウイルス（COVID-19）最新治療薬市場

  • 中国コロナウイルス（COVID-19）最新治療薬市場概要
  • 中国コロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 中国コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第10章 インドのコロナウイルス（COVID-19）最新治療薬市場

  • インドのコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • インドのコロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別のセグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第11章 日本のコロナウイルス（COVID-19）最新治療薬市場

  • 日本のコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別のセグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 日本コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第12章 オーストラリアのコロナウイルス（COVID-19）最新治療薬市場

  • オーストラリアのコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • オーストラリアのコロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別のセグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第13章 インドネシアのコロナウイルス（COVID-19）最新治療薬市場

  • インドネシアコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • インドネシアコロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第14章 韓国のコロナウイルス（COVID-19）最新治療薬市場

  • 韓国のコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 韓国コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第15章 西欧のコロナウイルス（COVID-19）最新治療薬市場

  • 西欧コロナウイルス（COVID-19）最新治療薬市場概要
  • 西欧のコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 西欧コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第16章 英国のコロナウイルス（COVID-19）最新治療薬市場

  • 英国のコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 英国コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第17章 ドイツのコロナウイルス（COVID-19）最新治療薬市場

  • ドイツコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • ドイツコロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第18章 フランスのコロナウイルス（COVID-19）最新治療薬市場

  • フランスコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • フランスコロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第19章 東欧のコロナウイルス（COVID-19）最新治療薬市場

  • 東欧コロナウイルス（COVID-19）最新治療薬市場概要
  • 東欧のコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 東欧コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第20章 ロシアのコロナウイルス（COVID-19）最新治療薬市場

  • ロシアコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • ロシアのコロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第21章 北米のコロナウイルス（COVID-19）最新治療薬市場

  • 北米コロナウイルス（COVID-19）最新治療薬市場概要
  • 北米コロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 北米コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第22章 米国のコロナウイルス（COVID-19）最新治療薬市場

  • 米国コロナウイルス（COVID-19）最新治療薬市場概要
  • 米国コロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 米国コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第23章 南米のコロナウイルス（COVID-19）最新治療薬市場

  • 南米コロナウイルス（COVID-19）最新治療薬市場概要
  • 南米のコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 南米コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第24章 ブラジルのコロナウイルス（COVID-19）最新治療薬市場

  • ブラジルコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • ブラジルコロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第25章 中東のコロナウイルス（COVID-19）最新治療薬市場

  • 中東コロナウイルス（COVID-19）最新治療薬市場概要
  • 中東コロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 中東コロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第26章 アフリカのコロナウイルス（COVID-19）最新治療薬市場

  • アフリカコロナウイルス（COVID-19）最新治療薬市場概要
  • アフリカコロナウイルス（COVID-19）最新治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • アフリカコロナウイルス（COVID-19）最新治療薬市場、エンドユーザー別のセグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第27章 コロナウイルス（COVID-19）最新治療薬市場の競合情勢と企業プロファイル

  • コロナウイルス（COVID-19）最新治療薬市場の競合情勢
  • コロナウイルス（COVID-19）最新治療薬市場の企業プロファイル
    • Moderna Therapeutics
    • Novavax
    • Bravovax
    • Ascletis Pharma
    • Altimmune

第28章 コロナウイルス（COVID-19）最新治療薬市場における主要な合併と買収

第29章 コロナウイルス（COVID-19）最新治療薬市場の将来の見通しと潜在的な分析

第30章 付録

目次
Product Code: r2044

“Coronavirus (COVID-19) Current Therapy Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on coronavirus (COVID-19) current therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for coronavirus (COVID-19) current therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The coronavirus (COVID-19) current therapy market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Type: Remdesivir; Hydroxychloroquine; Ritonavir; Lopinavir; Interferon Beta; Other Drug Type

2) By Route Of Administration: Oral; Intravenous

3) By End User: Hospitals; Clinics; Research Institutes; Other End Users

Companies Mentioned: Moderna Therapeutics; Novavax; Bravovax; Ascletis Pharma; Altimmune

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the coronavirus (COVID-19) current therapy market are: Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., Biocryst Pharma, Gilead Sciences, and Regeneron Pharmaceuticals.

The global coronavirus (COVID-19) current therapy market is expected to decline from $28.16 billion in 2021 to $16.43 billion in 2022 at a compound annual growth rate (CAGR) of -41.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The coronavirus (COVID-19) current therapy market is expected to decline to $1.57 billion in 2026 at a CAGR of -44.4%.

The coronavirus (COVID-19) current therapy market includes revenues earned by entities by tocilizumab, favipiravir, and ivermectin. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

Coronavirus (COVID-19) current therapy refers to a drug created and used to treat mild to moderate COVID-19 in those who have a higher risk of experiencing significant illness as a result of COVID-19.

North America is the largest region in the coronavirus (COVID-19) current therapy market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the coronavirus (COVID-19) current therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of drugs in coronavirus (COVID-19) current therapy are redeliver, hydroxychloroquine, ritonavir, lopinavir, interferon beta, and others. Remdesivir is an antiviral drug that works by preventing an RNA-based virus from replicating its viral genome within an infected cell. It was first used to combat the Ebola virus. It can be administered through various routes such as oral and intravenous. The different sectors include hospitals, clinics, and research institutes; others.

The outbreak of the pandemic COVID-19 contributed to the growth of the coronavirus (COVID-19) current therapy market. On March 11, 2020, the World Health Organization (WHO) declared the outbreak as a global pandemic. According to the World Health Organization (WHO), there were 10,719,946 cases of COVID-19 including 517,337 deaths reported to WHO on 3rd July 2020, and this number is expected to grow soon. As there is no officially approved drug for COVID-19, the demand has risen significantly for repurposed drugs that are used for corona therapy. Countries across the world are facing shortages of drugs and drug manufacturers are ramping up production to meet the global demand. Coronavirus Treatment Acceleration Program (CTAP) is a special emergency program initiated by the FDA for the development of potential COVID-19 therapies to be made available to the patients as quickly as possible.

High costs involved in the research and development of therapeutic drugs and vaccines and the long waiting time required for each phase of clinical trials are expected to limit the growth of the coronavirus (COVID-19) current therapy market. According to a recent study published in the Journal of Health Economics by the Tufts Center for the Study of Drug Development, it is estimated to cost $2.6 billion in developing a new prescription medicine and gain marketing approval, and seven out of eight pipeline drugs will fail in the development process. Moreover, the time required for each phase of the clinical trial and drug approval process takes an average of 12 years for an experimental drug to reach the market. High costs and long waiting times for drug development are expected to hamper the coronavirus (COVID-19) current therapy market.

Convalescent Plasma Therapy is used as an experimental therapy to treat COVID-19 patients. The blood plasma of patients who have recovered from a disease is called convalescent plasma (CP). Convalescent Plasma (CP) therapy is a type of passive antibody therapy in which blood plasma is isolated from patients who have recovered from the disease of interest and administered to the patient with severe disease to suppress the virulence and improve clinical symptoms. The blood plasma of recovered COVID-19 patients has antibodies to fight COVID-19 infection. According to guidance issued by the FDA, Convalescent Plasma Therapy is recommended as an investigational product during a public health emergency. By 30th April 2020, around 2,004 participating sites adhering to a single expanded access protocol by the US FDA had been registered, around 7,774 patients have enrolled, and 3,809 of them have undergone convalescent plasma transfusion. The experimental convalescent plasma therapy is likely to gain attention if enough data is supporting the results.

In March 2020, Sanofi and Regeneron Pharmaceuticals planned to initiate clinical trials of the rheumatoid arthritis drug Kevzara (sarilumab) for the treatment of COVID-19 symptoms. The US Food and Drug Administration (FDA) approved Kevzara to treat rheumatoid arthritis. The drug is part of an ongoing antibody partnership between Sanofi and Regeneron. Kevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor. IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19. Following a review by the Independent Data Monitoring Committee (IDMC) of all available Phase 2 and Phase 3 data, the trial will be immediately amended so that only critical patients continue to be enrolled to receive Kevzara 400 mg.

The countries covered in the coronavirus (COVID-19) current therapy market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The coronavirus (COVID-19) current therapy market research report is one of a series of new reports from The Business Research Company that provides coronavirus (COVID-19) current therapy market statistics, including coronavirus (COVID-19) current therapy industry global market size, regional shares, competitors with a coronavirus (COVID-19) current therapy market share, detailed coronavirus (COVID-19) current therapy market segments, market trends and opportunities, and any further data you may need to thrive in the coronavirus (COVID-19) current therapy industry. This coronavirus (COVID-19) current therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Table of Contents

1. Executive Summary

2. Coronavirus (COVID-19) Current Therapy Market Characteristics

3. Coronavirus (COVID-19) Current Therapy Market Trends And Strategies

4. Coronavirus (COVID-19) Current Therapy Market - Macro Economic Scenario

4.1 COVID-19 Impact On Coronavirus (COVID-19) Current Therapy Market

4.2 Ukraine-Russia War Impact On Coronavirus (COVID-19) Current Therapy Market

4.3 Impact Of High Inflation On Coronavirus (COVID-19) Current Therapy Market

5. Coronavirus (COVID-19) Current Therapy Market Size And Growth

  • 5.1. Global Coronavirus (COVID-19) Current Therapy Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Coronavirus (COVID-19) Current Therapy Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Coronavirus (COVID-19) Current Therapy Market Segmentation

  • 6.1. Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Remdesivir
  • Hydroxychloroquine
  • Ritonavir
  • Lopinavir
  • Interferon Beta
  • Other Drug Types
  • 6.2. Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Oral
  • Intravenous
  • 6.3. Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospitals
  • Clinics
  • Research Institutes
  • Other End Users

7. Coronavirus (COVID-19) Current Therapy Market Regional And Country Analysis

  • 7.1. Global Coronavirus (COVID-19) Current Therapy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Coronavirus (COVID-19) Current Therapy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Coronavirus (COVID-19) Current Therapy Market

  • 8.1. Asia-Pacific Coronavirus (COVID-19) Current Therapy Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 8.3. Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Coronavirus (COVID-19) Current Therapy Market

  • 9.1. China Coronavirus (COVID-19) Current Therapy Market Overview
  • 9.2. China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
  • 9.3. China Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Coronavirus (COVID-19) Current Therapy Market

  • 10.1. India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 10.2. India Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Coronavirus (COVID-19) Current Therapy Market

  • 11.1. Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 11.2. Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Coronavirus (COVID-19) Current Therapy Market

  • 12.1. Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 12.2. Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Coronavirus (COVID-19) Current Therapy Market

  • 13.1. Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 13.2. Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Coronavirus (COVID-19) Current Therapy Market

  • 14.1. South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 14.2. South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Coronavirus (COVID-19) Current Therapy Market

  • 15.1. Western Europe Coronavirus (COVID-19) Current Therapy Market Overview
  • 15.2. Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 15.3. Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Coronavirus (COVID-19) Current Therapy Market

  • 16.1. UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 16.2. UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Coronavirus (COVID-19) Current Therapy Market

  • 17.1. Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 17.2. Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Coronavirus (COVID-19) Current Therapy Market

  • 18.1. France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 18.2. France Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Coronavirus (COVID-19) Current Therapy Market

  • 19.1. Eastern Europe Coronavirus (COVID-19) Current Therapy Market Overview
  • 19.2. Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 19.3. Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Coronavirus (COVID-19) Current Therapy Market

  • 20.1. Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 20.2. Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Coronavirus (COVID-19) Current Therapy Market

  • 21.1. North America Coronavirus (COVID-19) Current Therapy Market Overview
  • 21.2. North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 21.3. North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Coronavirus (COVID-19) Current Therapy Market

  • 22.1. USA Coronavirus (COVID-19) Current Therapy Market Overview
  • 22.2. USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 22.3. USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Coronavirus (COVID-19) Current Therapy Market

  • 23.1. South America Coronavirus (COVID-19) Current Therapy Market Overview
  • 23.2. South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 23.3. South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Coronavirus (COVID-19) Current Therapy Market

  • 24.1. Brazil Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 24.2. Brazil Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Coronavirus (COVID-19) Current Therapy Market

  • 25.1. Middle East Coronavirus (COVID-19) Current Therapy Market Overview
  • 25.2. Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 25.3. Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Coronavirus (COVID-19) Current Therapy Market

  • 26.1. Africa Coronavirus (COVID-19) Current Therapy Market Overview
  • 26.2. Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 26.3. Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Coronavirus (COVID-19) Current Therapy Market Competitive Landscape And Company Profiles

  • 27.1. Coronavirus (COVID-19) Current Therapy Market Competitive Landscape
  • 27.2. Coronavirus (COVID-19) Current Therapy Market Company Profiles
    • 27.2.1. Moderna Therapeutics
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Novavax
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Bravovax
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Ascletis Pharma
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Altimmune
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Coronavirus (COVID-19) Current Therapy Market

29. Coronavirus (COVID-19) Current Therapy Market Future Outlook and Potential Analysis

30. Appendix

  • 30.1. Abbreviations
  • 30.2. Currencies
  • 30.3. Historic And Forecast Inflation Rates
  • 30.4. Research Inquiries
  • 30.5. The Business Research Company
  • 30.6. Copyright And Disclaimer